Nicorandil after heart attack to protect small heart vessels
Treatments studied
Part of Heart & circulation clinical trials.
This study tests if the medicine nicorandil can help protect the tiny blood vessels in the heart in the first hours after a heart attack (STEMI) when you get a stent. It aims to improve blood flow and heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had a specific type of heart attack called STEMI, and your doctor plans to open the blocked artery with a balloon and stent (primary PCI).
- The blocked artery is at least 2 mm wide and is the main cause of your heart attack.
- You have no serious liver or kidney problems, and you are not in cardiogenic shock (needing a machine to help your heart pump).
- You are not allergic to any test medicine, and your blood pressure is above 85 mmHg before the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a medicine (nicorandil) given into a coronary artery during stent procedures can help keep blood flow from getting worse. It may help people having stent placement for coronary artery disease by improving how well blood moves through the treated area.
This study tests whether a heart medication called nicorandil can help reduce arthritis symptoms when added to your current treatment. It is for people with moderate to severe rheumatoid arthritis who have been stable on their current treatments.
This trial tests treatments for small blood vessel damage after a major heart attack (STEMI). If you have had a heart attack and are receiving a stent, this study may help improve recovery by targeting microvascular injury.
This study tests whether nicorandil, a heart medication with anti-inflammatory properties, can help reduce joint inflammation and swelling in people with active rheumatoid arthritis who are already taking conventional disease-modifying drugs. The goal is to see if it provides additional relief from symptoms.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests whether a medication called ranolazine can help prevent damage to tiny blood vessels in the heart after a certain type of heart attack (STEMI). You may be eligible if you recently had this kind of heart attack and had a successful procedure to open a blocked artery, but still have other blockages that can be treated with stents.
Hear when a new STEMI - ST-segment Elevation Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.